TARSUS PHARMACEUTICALS, INC. Temporary Equity, Liquidation Preference
TARSUS PHARMACEUTICALS, INC. (TARS) had Temporary Equity, Liquidation Preference of $103.66 million as of 2020-09-30, per its 10-Q filed 2020-11-25.
Discontinued › Balance Sheet › Temporary Equity › Temporary Equity, Other Disclosure
us-gaap:TemporaryEquityLiquidationPreference · last filed 2021-03-31
- 2020-09-30: Temporary Equity, Liquidation Preference $103.66M.
- 2019-12-31: Temporary Equity, Liquidation Preference $63.66M.
| Period end | Temporary Equity, Liquidation Preference |
|---|---|
| 2020-09-30 | $103.66M 10-Q · filed 2020-11-25 |
| 2019-12-31 | $63.66M 10-K · filed 2021-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |